China-Based WuXi Biologics Selects Cranbury, New Jersey for Third U.S. Clinical Manufacturing Campus
06/10/2020
This news follows WuXi Biologics' recent purchase of land to build a new 107,000-square-foot clinical and commercial manufacturing facility in Worcester, Massachusetts, and the lease of a 33,000-square-foot site to establish a process development lab in King of Prussia, Pennsylvania.
According to company officials, the New Jersey clinical manufacturing facility will include 6000 L bioreactors, Process Development, Quality Control labs, along with supporting functions. The 66,000-square-foot facility is expected to become operational in late 2020 and will bring in up to 100 jobs to the region.
"We are excited to announce our third site in the United States and proud to become a member of the New Jersey community. Cranbury is a growing hub for the biotech and biopharma industries and we look forward to working with and serving our partners in the area to benefit patients worldwide," said Dr. Chris Chen, CEO of WuXi Biologics.
WuXi Biologics, a Hong Kong-listed company, noted it is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing.
Most Read
-
-
What’s Driving Record Industrial Real Estate Demand
Q1 2021
-
2020 Top States for Doing Business Showcase Their Pro-Business Environments
Q3 2020
-
2020 Gold & Silver Shovel Awards Recognize State and Local Economic Development Efforts
Q2 2020
-
35th Annual Survey of Corporate Executives Commentary: Change in Site Selection Priorities and Plans Over the Short and Long Term
Q1 2021
-
17th Annual Consultants Survey: Consultants Are Optimistic About the Year Ahead
Q1 2021
-
Challenges of Moving Manufacturing Out of China
Q1 2021